News

Researchers at the National Brain Research Centre in India have shown that inhibitors of the proteins HDAC1/2 might be a potential therapeutic for the treatment of Angelman syndrome (AS) as increased activity of the HDAC1/2 causes brain dysfunction and behavioral issues in mice with AS. The study, “Rescue…

A new, revised protocol of the non-invasive prenatal test (NIPT) Panorama identifies genetic abnormalities underlying Angelman and four other syndromes with higher accuracy and efficiency than the original test, a study found. The study, “Clinical Experience with a Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Test for Five Clinically Significant…

Roche and representatives of parent-driven organizations are collaborating on the first part of a study whose objective is to design better clinical trials and speed up the development of Angelman syndrome treatments. The aim of the initial part of the study is to gain a…

A recent review highlights the latest findings on the role of a group of molecules called long noncoding RNAs (lncRNAs) in neurodevelopmental disorders such as Angelman syndrome. The review, titled “Long noncoding RNA and its contribution to autism spectrum disorders,” was published in the journal CNS Neuroscience & Therapeutics.

Dennis Vanderheiden of Fort Collins, Colorado, is propelling two people forward as he cycles 585 miles in 13 days across his home state to raise money for Angelman syndrome research. A buddy with the disorder, Paul James (P.J.) Snyder, is riding in the bike trailer that Vanderheiden pulls across Colorado’s…

ANAVEX 2-73 significantly reduced sound-triggered seizures in mice with Angelman syndrome, according to a preclinical-trial study. Its developer, Anavex Life Sciences, reported the results at the Antiepileptic Drug Trials XIV 2017 Conference  in North Miami Beach, May 17-19. The presentation was titled “ANAVEX 2-73,…

Ovid Therapeutics is conducting two clinical trials assessing its lead candidate OV101 for the treatment of adolescents and adults with Angelman syndrome. Both trials are currently enrolling participants. “Ovid has a clear strategy and business plan to build a neurology company focused on rare disorders of the brain,” Jeremy…